LSL Pharma Group Balance Sheet Health
Financial Health criteria checks 3/6
LSL Pharma Group has a total shareholder equity of CA$9.8M and total debt of CA$11.3M, which brings its debt-to-equity ratio to 115.8%. Its total assets and total liabilities are CA$29.7M and CA$19.9M respectively.
Key information
115.8%
Debt to equity ratio
CA$11.29m
Debt
Interest coverage ratio | n/a |
Cash | CA$513.64k |
Equity | CA$9.75m |
Total liabilities | CA$19.90m |
Total assets | CA$29.65m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: LSL's short term assets (CA$6.0M) do not cover its short term liabilities (CA$14.2M).
Long Term Liabilities: LSL's short term assets (CA$6.0M) exceed its long term liabilities (CA$5.7M).
Debt to Equity History and Analysis
Debt Level: LSL's net debt to equity ratio (110.5%) is considered high.
Reducing Debt: Insufficient data to determine if LSL's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LSL has sufficient cash runway for 1 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: LSL is forecast to have sufficient cash runway for 0 months based on free cash flow estimates, but has since raised additional capital.